Picture EBD Group BIO-Europe Spring 2021 Digital 650x80
Document › Details

Calliditas Therapeutics AB. (7/24/20). "Press Release: Calliditas Reorganizes Its Management Team".

Organisation Organisation Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
  Group Calliditas Therapeutics (Group)
Products Product Nefecon®
  Product 2 drug development
Persons Person Aguiar-Lucander, Renée (Pharmalink AB 201708 CEO)
  Person 2 Johansson, Fredrik (Pharmalink AB 201708– CFO before Birdstep Technology/Techstep ASA)

Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that it has reorganized its management team.

From today, the company’s management team will consist of:

Renée Aguiar-Lucander, CEO

Fredrik Johansson, CFO

Dr Richard Philipson, CMO

Frank Bringstrup, Vice President Regulatory Affairs

Andrew Udell, Head of North America, Commercial

Katayoun Welin-Berger, Vice President Operations

“Calliditas will continue to build and benefit from a broad and highly competent senior team which operates in an integrated manner. As the company has grown there is now need for a smaller and more focused executive group to support this structure and continue to leverage this cross functional expertise.”, said CEO Renée Aguiar-Lucander.

Due to the growing number of employees in the US, Andrew Udell has been appointed as Head of North America, Commercial and will be responsible for implementation and execution of medical affairs, market access, as well as sales and marketing in the US.

For further information, please contact:

Renée Aguiar-Lucander, CEO at Calliditas
Tel.: +46 722 52 10 06, email:

Mikael Widell, Head of Communications and IR
Tel.: +46 703 11 99 60, email:

The information was sent for publication, through the agency of the contact persons set out above, on July 24, 2020 at 8:00 a.m. CET.

About Calliditas

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas’ lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit for further information.

Record changed: 2020-10-21


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Calliditas Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top